Company / Revenue per Share
FATE THERAPEUTICS INC Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.12
FY2025
5-year range
$0.12 / $0.99
FY2021-FY2025
Trend
-81.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share has fluctuated over the past 9 years, ranging from $0.05 in FY2016 to $0.99 in FY2023.
Based on SEC 10-K filings.
0.12 in FY2025 with a 5-year CAGR of +13.8%.
Declined from $0.99 to $0.12 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -28.6%
- 5-Year CAGR
- +13.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share decreased 81.4% year-over-year.
- Peak revenue per share was recorded in FY2023.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.12 | -81.4% |
| FY2024 | $0.64 | -34.9% |
| FY2023 | $0.99 | +201.4% |
| FY2022 | $0.33 | +169.7% |
| FY2021 | $0.12 | +94.5% |
| FY2020 | $0.06 | -1.4% |
| FY2019 | $0.06 | -24.1% |
| FY2018 | $0.08 | - |
| FY2017 | - | - |
| FY2016 | $0.05 | -2.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026